These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34228837)

  • 1. Urinary peptidome and diabetic retinopathy in the DIRECT-Protect 1 and 2 trials.
    Rotbain Curovic V; Magalhães P; He T; Hansen TW; Mischak H; Rossing P;
    Diabet Med; 2021 Sep; 38(9):e14634. PubMed ID: 34228837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study.
    Lindhardt M; Persson F; Zürbig P; Stalmach A; Mischak H; de Zeeuw D; Lambers Heerspink H; Klein R; Orchard T; Porta M; Fuller J; Bilous R; Chaturvedi N; Parving HH; Rossing P
    Nephrol Dial Transplant; 2017 Nov; 32(11):1866-1873. PubMed ID: 27507891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.
    Chaturvedi N; Porta M; Klein R; Orchard T; Fuller J; Parving HH; Bilous R; Sjølie AK;
    Lancet; 2008 Oct; 372(9647):1394-402. PubMed ID: 18823656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics.
    Sjølie AK; Porta M; Parving HH; Bilous R; Klein R;
    J Renin Angiotensin Aldosterone Syst; 2005 Mar; 6(1):25-32. PubMed ID: 16088848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
    Sjølie AK; Klein R; Porta M; Orchard T; Fuller J; Parving HH; Bilous R; Aldington S; Chaturvedi N
    Diabet Med; 2011 Mar; 28(3):345-51. PubMed ID: 21309844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.
    Sjølie AK; Klein R; Porta M; Orchard T; Fuller J; Parving HH; Bilous R; Chaturvedi N;
    Lancet; 2008 Oct; 372(9647):1385-93. PubMed ID: 18823658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic retinopathy and blockade of the renin-angiotensin system: new data from the DIRECT study programme.
    Wright AD; Dodson PM
    Eye (Lond); 2010 Jan; 24(1):1-6. PubMed ID: 19648902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
    Lambers Heerspink HJ; Weldegiorgis M; Inker LA; Gansevoort R; Parving HH; Dwyer JP; Mondal H; Coresh J; Greene T; Levey AS; de Zeeuw D
    Am J Kidney Dis; 2014 Feb; 63(2):244-50. PubMed ID: 24210590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin receptor blockade not related to history of dry eye symptoms and treatment in The Diabetic Retinopathy Candesartan Trials (DIRECT).
    Moss SE; Klein R; Sjølie AK; Chaturvedi N; Malm AR; Fuller JH; Porta M;
    Acta Ophthalmol; 2011 Sep; 89(6):e535-6. PubMed ID: 20809912
    [No Abstract]   [Full Text] [Related]  

  • 10. DIRECT new treatments for diabetic retinopathy.
    Mitchell P; Wong TY
    Lancet; 2008 Oct; 372(9647):1361-3. PubMed ID: 18823657
    [No Abstract]   [Full Text] [Related]  

  • 11. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
    Schutte E; Lambers Heerspink HJ; Lutgers HL; Bakker SJ; Vart P; Wolffenbuttel BH; Umanath K; Lewis JB; de Zeeuw D; Gansevoort RT
    Am J Kidney Dis; 2015 Sep; 66(3):450-8. PubMed ID: 25987260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
    Bilous R; Chaturvedi N; Sjølie AK; Fuller J; Klein R; Orchard T; Porta M; Parving HH
    Ann Intern Med; 2009 Jul; 151(1):11-20, W3-4. PubMed ID: 19451554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential clinical profile of candesartan compared to other angiotensin receptor blockers.
    Cernes R; Mashavi M; Zimlichman R
    Vasc Health Risk Manag; 2011; 7():749-59. PubMed ID: 22241949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?
    Weldegiorgis M; de Zeeuw D; Dwyer JP; Mol P; Heerspink HJL
    Clin J Am Soc Nephrol; 2017 Oct; 12(10):1595-1600. PubMed ID: 28923834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study.
    Baguet JP; Asmar R; Valensi P; Nisse-Durgeat S; Mallion JM
    Vasc Health Risk Manag; 2009; 5(1):175-83. PubMed ID: 19436670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The Diabetic Retinopathy Candesartan Trials (DIRECT) programme].
    Ohashi H; Takagi H
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():297-301. PubMed ID: 15999723
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
    Rosei EA; Rizzoni D; Muiesan ML; Sleiman I; Salvetti M; Monteduro C; Porteri E;
    J Hypertens; 2005 Feb; 23(2):435-44. PubMed ID: 15662233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review.
    Sjølie AK; Dodson P; Hobbs FR
    Int J Clin Pract; 2011 Feb; 65(2):148-53. PubMed ID: 21235695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candesartan: widening indications for this angiotensin II receptor blocker?
    Mendis B; Page SR
    Expert Opin Pharmacother; 2009 Aug; 10(12):1995-2007. PubMed ID: 19563275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.